Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Paragon 28, Inc. stock logo
FNA
Paragon 28
$13.11
+0.1%
$13.11
$4.65
$13.13
$1.10B1.471.19 million shs19.38 million shs
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
$14.54
-0.4%
$14.86
$8.26
$19.41
$1.24B-0.011.30 million shs1.77 million shs
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
$15.10
-3.5%
$16.20
$13.50
$25.00
$1.02B1.56173,968 shs210,216 shs
RxSight, Inc. stock logo
RXST
RxSight
$7.35
-0.4%
$13.32
$6.32
$58.23
$298.70M1.21819,912 shs1.25 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.00%0.00%0.00%0.00%+61.79%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
0.00%+3.19%+10.40%+9.41%+31.23%
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
0.00%-5.80%-1.31%-12.67%-5.39%
RxSight, Inc. stock logo
RXST
RxSight
0.00%-8.13%-46.00%-48.24%-84.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/AN/AN/AN/A
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
3.2635 of 5 stars
4.50.00.00.01.84.20.6
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
2.8068 of 5 stars
3.50.00.04.20.04.20.0
RxSight, Inc. stock logo
RXST
RxSight
2.3397 of 5 stars
4.01.00.00.01.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Paragon 28, Inc. stock logo
FNA
Paragon 28
2.20
Hold$12.75-2.71% Downside
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
3.00
Buy$26.8984.93% Upside
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
3.00
Buy$22.0045.70% Upside
RxSight, Inc. stock logo
RXST
RxSight
1.91
Reduce$17.50138.10% Upside

Current Analyst Ratings Breakdown

Latest RXST, LQDA, FNA, and PLSE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2025
RxSight, Inc. stock logo
RXST
RxSight
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$20.00 ➝ $9.00
7/10/2025
RxSight, Inc. stock logo
RXST
RxSight
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$24.00 ➝ $9.00
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$18.00 ➝ $9.00
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$18.00 ➝ $10.00
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$17.00 ➝ $9.00
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$25.00 ➝ $9.00
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
7/7/2025
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$22.00
6/12/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$23.00 ➝ $25.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Paragon 28, Inc. stock logo
FNA
Paragon 28
$256.18M4.29N/AN/A$2.05 per share6.39
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
$14M88.79N/AN/A$0.91 per share15.98
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
$700K1,451.11N/AN/A$1.87 per share8.07
RxSight, Inc. stock logo
RXST
RxSight
$139.93M2.13N/AN/A$6.98 per share1.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$57.53M-$0.63N/AN/AN/A-25.31%-37.90%-18.22%N/A
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$130.39M-$1.58N/AN/AN/A-903.80%-177.91%-60.15%8/6/2025 (Estimated)
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
-$53.58MN/A0.00N/AN/A-68.44%-58.17%8/14/2025 (Estimated)
RxSight, Inc. stock logo
RXST
RxSight
-$27.45M-$0.67N/AN/AN/A-17.90%-9.54%-8.51%8/7/2025 (Estimated)

Latest RXST, LQDA, FNA, and PLSE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
-$0.26N/AN/AN/AN/AN/A
8/7/2025Guidance Update
RxSight, Inc. stock logo
RXST
RxSight
-$0.0363N/AN/AN/A$39.78 millionN/A
8/6/2025Q2 2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$0.43N/AN/AN/A$3.90 millionN/A
5/8/2025Q1 2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million
5/8/2025Q1 2025
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
N/A-$0.25N/A-$0.25N/AN/A
5/7/2025Q1 2025
RxSight, Inc. stock logo
RXST
RxSight
-$0.03-$0.03N/A-$0.20$38.74 million$37.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/A
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
N/AN/AN/AN/AN/A
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/A
RxSight, Inc. stock logo
RXST
RxSight
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.79
3.50
1.60
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
2.08
2.93
2.91
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
N/A
15.58
15.58
RxSight, Inc. stock logo
RXST
RxSight
N/A
12.68
11.65

Institutional Ownership

CompanyInstitutional Ownership
Paragon 28, Inc. stock logo
FNA
Paragon 28
63.57%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
64.54%
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
76.95%
RxSight, Inc. stock logo
RXST
RxSight
78.78%

Insider Ownership

CompanyInsider Ownership
Paragon 28, Inc. stock logo
FNA
Paragon 28
15.32%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
30.10%
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
71.50%
RxSight, Inc. stock logo
RXST
RxSight
9.57%
CompanyEmployeesShares OutstandingFree FloatOptionable
Paragon 28, Inc. stock logo
FNA
Paragon 28
343,00083.94 million70.89 millionOptionable
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
5085.49 million59.75 millionOptionable
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
14067.27 million19.17 millionOptionable
RxSight, Inc. stock logo
RXST
RxSight
22040.64 million36.75 millionOptionable

Recent News About These Companies

Morgan Stanley Downgrades RxSight (RXST)
Brokerages Set RxSight, Inc. (NASDAQ:RXST) PT at $30.20

New MarketBeat Followers Over Time

Media Sentiment Over Time

Paragon 28 stock logo

Paragon 28 NYSE:FNA

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Liquidia Technologies stock logo

Liquidia Technologies NASDAQ:LQDA

$14.54 -0.06 (-0.41%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$14.74 +0.20 (+1.38%)
As of 07/18/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Pulse Biosciences stock logo

Pulse Biosciences NASDAQ:PLSE

$15.10 -0.55 (-3.51%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$15.12 +0.02 (+0.13%)
As of 07/18/2025 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

RxSight stock logo

RxSight NASDAQ:RXST

$7.35 -0.03 (-0.41%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$7.45 +0.10 (+1.31%)
As of 07/18/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.